Radioresistance of prostate cancer cells with low proteasome activity

Prostate

Volumn 72, Issue 8, 2012, Pages 868-874

  Della Donna, Lorenza ^a   Lagadec, Chann ^a   Pajonk, Frank ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

proteasome; radioresistance; self renewal; tumorigenicity

Indexed keywords

26S PROTEASOME; PROTEASOME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER RESISTANCE; CARCINOGENICITY; CELL RENEWAL; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IONIZING RADIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RADIOSENSITIVITY;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MICE; MICE, NUDE; PHENOTYPE; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RADIATION TOLERANCE; RADIOTHERAPY; TREATMENT FAILURE;

EID: 84860335684     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21489     Document Type: Article

References (18)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (5): 277-300.
2. Freedland SJ,. Screening, risk assessment, and the approach to therapy in patients with prostate cancer. Cancer 2011; 117 (6): 1123-1135.
3. Alicikus ZA, Yamada Y, Zhang Z, Pei X, Hunt M, Kollmeier M, Cox B, Zelefsky MJ,. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer 2011; 117 (7): 1429-1437.
4. Stavridi F, Karapanagiotou EM, Syrigos KN,. Targeted therapeutic approaches for hormone-refractory prostate cancer. Cancer Treat Rev 2010; 36 (2): 122-130.
5. Pajonk F, McBride WH,. The proteasome in cancer biology and treatment. Radiat Res 2001; 156 (5): 447-459. (Pubitemid 33027513)
6. Coux O,. The 26S proteasome. Prog Mol Subcell Biol 2002; 29: 85-107.
7. Pajonk F, Himmelsbach J, Riess K, Sommer A, McBride WH,. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 2002; 62 (18): 5230-5235. (Pubitemid 35024595)
8. Pajonk F, van Ophoven A, Weissenberger C, McBride WH,. The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism. BMC Cancer 2005; 5 (1): 76.
9. Morris MJ, Kelly WK, Slovin S, Ryan C, Eicher C, Heller G, Scher HI,. A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer. J Urol 2007; 178 (6): 2378-2383; discussion 2383-2384.
10. LoConte NK, Thomas JP, Alberti D, Heideman J, Binger K, Marnocha R, Utecht K, Geiger P, Eickhoff J, Wilding G, Kolesar J,. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer. Cancer Chemother Pharmacol 2008; 63 (1): 109-115.
11. Hainsworth JD, Meluch AA, Spigel DR, Barton J Jr, Simons L, Meng C, Gould B, Greco FA,. Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: A Minnie Pearl Cancer Research Network phase II trial. Clin Genitourin Cancer 2007; 5 (4): 278-283. (Pubitemid 46867364)
12. Dreicer R, Petrylak D, Agus D, Webb I, Roth B,. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res 2007; 13 (4): 1208-1215. (Pubitemid 46424062)
13. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ,. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22 (11): 2108-2121. (Pubitemid 41095144)
14. Vlashi E, Kim K, Dealla Donna L, Lagadec C, McDonald T, Eghbali M, Sayre J, Stefani E, McBride W, Pajonk F,. In-vivo imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst 2009; 101 (5): 350-359.
15. Lagadec C, Vlashi E, Della Donna L, Meng Y, Dekmezian C, Kim K, Pajonk F,. Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment. Breast Cancer Res 2010; 12 (1): R13.
16. Vlashi E, Kim K, Lagadec C, Donna LD, McDonald JT, Eghbali M, Sayre JW, Stefani E, McBride W, Pajonk F,. In vivo imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst 2009; 101 (5): 350-359.
17. Pan J, Zhang Q, Wang Y, You M,. 26S proteasome activity is down-regulated in lung cancer stem-like cells propagated in vitro. PLoS ONE 2010; 5 (10): e13298.
18. Smith L, Qutob O, Watson MB, Beavis AW, Potts D, Welham KJ, Garimella V, Lind MJ, Drew PJ, Cawkwell L,. Proteomic identification of putative biomarkers of radiotherapy resistance: A possible role for the 26S proteasome? Neoplasia 2009; 11 (11): 1194-1207.